Find AI Tools
Genesis Therapeutics screenshot

What is Genesis Therapeutics?

Genesis Therapeutics is a biotech company that uses artificial intelligence to discover new drug molecules. The company combines deep learning with physics-based machine learning through two proprietary tools: the GEMS platform and the Pearl foundation model. These tools are designed to predict how drug molecules interact with protein targets, then identify promising small-molecule candidates for development. The company works with pharmaceutical partners to apply its AI technology to their research programmes, whilst also developing its own pipeline of AI-discovered medicines. Genesis focuses on difficult protein targets that have traditionally been hard to drug, aiming to reduce the time and cost of early-stage drug discovery.

Key Features

GEMS platform

Proprietary system that combines deep learning and physics-based machine learning for molecular prediction

Pearl foundation model

A trained AI model designed to understand and predict protein-ligand interactions

Protein-ligand prediction

AI-driven prediction of how drug molecules bind to and interact with target proteins

Small-molecule candidate identification

Automated discovery of potential drug candidates across disease areas

Pharma partnership capability

Integration with pharmaceutical companies' existing research pipelines

Pros & Cons

Advantages

  • Addresses challenging protein targets that are difficult to drug using conventional methods
  • Combines multiple machine learning approaches rather than relying on a single technique
  • Backed by experienced biotech team with access to pharma partnerships and funding
  • Freemium model allows some access without upfront costs

Limitations

  • As an early-stage discovery tool, results still require validation through traditional wet-lab testing and clinical trials
  • Limited public information available about specific performance metrics or success rates compared to competitors
  • Intended primarily for pharmaceutical organisations rather than individual researchers or small teams

Use Cases

Pharmaceutical companies screening potential drug candidates for hard-to-drug protein targets

Biotech firms accelerating their small-molecule discovery programmes

Academic research groups exploring protein-ligand interactions at scale

Drug development teams prioritising which molecules to synthesise and test first